amylin glp-1 dual agonist Amycretin — a novel obesity treatment that targets both and receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD Weight loss medicine is entering

Diabetes and hypertension were also more prevalent among users

It is important to counsel patients that GI adverse effects are transient, and any loss of glycaemic control will be temporary, until the dose is uptitrated

10.1097/MNH.0b013e3283414d40 93

doi: 10.1016/S0140-6736(21)01324-6 [DOI] [PubMed] [Google Scholar] 191.Fras JP, Davies MJ, Rosenstock J, et al

Abstract The identification of amylin as a glucoregulatory peptide hormone with roles in meal-ending satiation sparked a surge of experimental development, which culminated in the amylin mimetic drug pramlintide

The wide use of these drugs and their adverse effects, although rare, need to be considered and calculated by patients who are using the drugs for weight